Switching to cyclosporine ophthalmic solution 0.09% improves signs and symptoms in patients with DED

In adults with dry eye disease that was not adequately controlled with cyclosporine ophthalmic emulsion 0.05%, switching to cyclosporine ophthalmic solution 0.09% was associated with statistically significant improvements in both signs and symptoms of dry eye over 12 weeks, according to a study.

The single-arm, open-label trial, included adults with a history and clinical diagnosis of dry eye disease for at least 3 months who had previously been treated with cyclosporine ophthalmic emulsion 0.05% but continued to experience insufficient disease control. Patients administered 1 drop of cyclosporine ophthalmic solution 0.09% in both eyes twice daily for 12 weeks.

A total of 124 patients were included in the intent-to-treat population. Mean changes from baseline in total corneal fluorescein staining and mSANDE scores were statistically significant at weeks 4, 8, and 12 (P < 0.0001 for all time points).

By week 12, statistically significant improvements from baseline were also observed in total conjunctival staining score, central corneal fluorescein staining score, Schirmer test score, and frequency of artificial tear use (P ≤ 0.0029). In addition, 69.4% of patients reported a preference for cyclosporine ophthalmic solution 0.09%.

Reference
Johnston J, Adler R, Hessen M, et al. Effect of Cyclosporine Ophthalmic Solution 0.09% on Signs and Symptoms of Dry Dye Disease in Patients Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%: Results from a Single-Arm, Open-Label, Phase 4 Study. Clin Ophthalmol. 2026;20:583071. doi: 10.2147/OPTH.S583071. PMID: 41809208; PMCID: PMC12968827.